An introduction to the Office of Drug Control’s Medicinal Cannabis Framework including requirements for Cultivation & Production, Manufacture, and Importation.
Presentation: Quality standards for medicinal cannabis: The requirements of T...TGA Australia
TGO 93 sets quality standards for medicinal cannabis products to address concerns about variation in cannabinoid content and potential contamination. It requires identification and testing of cannabis plants and limits on contaminants and adulterants in products. TGO 93 incorporates quality standards from the European Pharmacopoeia and requires validation and reporting of testing methods used by manufacturers. The TGO aims to improve quality and consistency of medicinal cannabis available in Australia when it takes effect.
Presentation: Commonwealth access schemes relevant to supply of medicinal can...TGA Australia
Overview of the scheduling of cannabis and tetrahydrocannabinols for human therapeutic use in certain circumstances, and details of the pathways available to access unapproved medicinal cannabis products.
TGA presentation: Medicinal cannabis cultivation and manufacture updateTGA Australia
This presentation provides an overview developments around quality requirements and standards for manufactured and raw material for medicinal cannabis.
TGA presentation: Legislation and patient access schemes for medicinal cannabisTGA Australia
This presentation provides an update on the current progress of the development of clinical guidance on the use of medicinal cannabis products in Australia.
The document discusses herbal drug regulation in India. It provides an overview of the types of herbal formulations regulated in India, the advantages of herbal drugs, market statistics, and the various schedules and rules that govern herbal drugs under the Drugs and Cosmetics Act. It also discusses Ayush regulations for herbal drugs, requirements for clinical trials, and issues related to promoting herbal drugs in India. The future prospects section outlines opportunities to improve regulation and development of the herbal drug industry in India.
Pharmaceutical Licecnsing authorites of indiaAtul Bhombe
Central Drug Standard Control Organisation (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. It regulates the import of drugs, approves new drugs and clinical trials. CDSCO works with six zonal offices, seven sub-zonal offices, and thirteen port/airport offices. The Drug Controller General of India, who is responsible for new drug, medical device, and clinical trial approvals, advises CDSCO. At the state level, State Licensing Authorities regulate and control the licensing of drug manufacturing, distribution, and sale within the state.
Presentation: Quality standards for medicinal cannabis: The requirements of T...TGA Australia
TGO 93 sets quality standards for medicinal cannabis products to address concerns about variation in cannabinoid content and potential contamination. It requires identification and testing of cannabis plants and limits on contaminants and adulterants in products. TGO 93 incorporates quality standards from the European Pharmacopoeia and requires validation and reporting of testing methods used by manufacturers. The TGO aims to improve quality and consistency of medicinal cannabis available in Australia when it takes effect.
Presentation: Commonwealth access schemes relevant to supply of medicinal can...TGA Australia
Overview of the scheduling of cannabis and tetrahydrocannabinols for human therapeutic use in certain circumstances, and details of the pathways available to access unapproved medicinal cannabis products.
TGA presentation: Medicinal cannabis cultivation and manufacture updateTGA Australia
This presentation provides an overview developments around quality requirements and standards for manufactured and raw material for medicinal cannabis.
TGA presentation: Legislation and patient access schemes for medicinal cannabisTGA Australia
This presentation provides an update on the current progress of the development of clinical guidance on the use of medicinal cannabis products in Australia.
The document discusses herbal drug regulation in India. It provides an overview of the types of herbal formulations regulated in India, the advantages of herbal drugs, market statistics, and the various schedules and rules that govern herbal drugs under the Drugs and Cosmetics Act. It also discusses Ayush regulations for herbal drugs, requirements for clinical trials, and issues related to promoting herbal drugs in India. The future prospects section outlines opportunities to improve regulation and development of the herbal drug industry in India.
Pharmaceutical Licecnsing authorites of indiaAtul Bhombe
Central Drug Standard Control Organisation (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. It regulates the import of drugs, approves new drugs and clinical trials. CDSCO works with six zonal offices, seven sub-zonal offices, and thirteen port/airport offices. The Drug Controller General of India, who is responsible for new drug, medical device, and clinical trial approvals, advises CDSCO. At the state level, State Licensing Authorities regulate and control the licensing of drug manufacturing, distribution, and sale within the state.
This document outlines administrative order no. 2014-0034 from the Philippines Department of Health Food and Drug Administration. It establishes rules for licensing drug establishments to ensure compliance with Good Manufacturing Practice, Good Distribution Practice, and other standards. It prescribes the use of electronic submissions and signatures. The order classifies different types of drug establishments and outlines requirements for licensing, variations, renewals, and inspections. It aims to align drug establishment operations with laws and international regulatory standards to ensure safety, efficacy and quality of drugs.
Dr.Lavanya- Laws pertaining to Ayurvedic drugsDr.Lavanya .S.A
This document summarizes various laws governing Ayurvedic drugs in India, including the Drug & Cosmetic Act of 1940, Drug & Magic Remedies Act of 1954, Prevention of Food Adulteration Act, Food Standards and Safety Act of 2006, and Narcotic Drugs and Psychotropic Substances Act of 1985. It provides details on key parts of acts like the Drug & Cosmetic Rules of 1945 and amendments made for regulation of Ayurvedic drugs. The document also lists some scheduled poisons and permitted excipients in Ayurvedic medicines.
This presentation contains legal requirements for labeling for pharmaceuticals, types of label, objective of label and recent advancement in labeling of pharmaceuticals.
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
This document outlines the regulatory requirements and approval procedures for drugs, cosmetics, medical devices, biological products, herbal medicines, and foods/nutraceuticals in India. It discusses the key regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the application processes. For drugs, the new drug approval procedure is described involving applying to the DCGI and undergoing clinical trials and reviews. For other products, the document explains the application forms and documents required for approval from bodies like FSSAI.
The passage summarizes the major changes to food and drug regulation in the Philippines from the passage of the Food and Drug Administration Act of 2009. Key points:
- The new law created the Food and Drug Administration (FDA) under the Department of Health, headed by a Director-General, to oversee food, drug, medical device, and cosmetic regulation.
- It consolidated regulatory powers over these products under the FDA, affecting two existing agencies. The new law aims to protect public health and establish an effective regulatory system.
- Major changes include new powers for the FDA, reorganization within the Department of Health, and establishment of new units within the FDA. The FDA has since drafted new rules and
A drug inspector is responsible for monitoring and ensuring the safety, quality, and effectiveness of drugs from production to sale. To become a drug inspector, candidates must have a pharmacy or pharmaceutical science degree, 18 months of relevant work experience, and pass a written exam consisting of two papers testing knowledge of pharmacy and general knowledge. Drug inspectors have the power to inspect any premises or records involved in drug manufacturing, sample and test drugs, inspect licenses, and cancel licenses of businesses found to have quality or standards issues. The role requires skills in discipline, patience, self-confidence, and keeping updated in the pharmaceutical field.
(15 mph104) cdsco & fda guidelinesDishant shah
This document provides an overview of CDSCO and FDA guidelines for drug approval. It begins with an introduction to CDSCO as India's national regulatory body equivalent to agencies like the EMA and FDA. It describes CDSCO's organization, functions in approving drugs and devices, and guidelines. It then explains the Common Technical Document format used for drug submissions and its modules. Guidelines for areas like cosmetics, clinical trials, and bioavailability and bioequivalence are summarized. The document concludes with references to CDSCO and FDA websites for further information.
The document summarizes the key proposed amendments to the Drugs and Cosmetics Act from the 2013 bill. It outlines the establishment of a new Central Drugs Authority to regulate the import, manufacture, and sale of drugs, cosmetics and medical devices. It also creates new chapters on clinical trials, requiring permission and registration for any trials. Penalties are established for violations like conducting unauthorized trials or failing to provide proper compensation. The bill aims to modernize drug regulation in India through the new oversight body and additional rules for clinical research.
The European Commission Health and Consumers Directorate – General has published a draft “GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICES FOR ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE”.
The guideline addresses Quality systems, Personnel, Documentation, Order, Procedures, Records, Premises and Equipment, Receipts, Storage , Deliveries to Customers, Transfer of Information and Returns.
Following presentation is prepared by “ Drug Regulations” a non profit organization which provides free online resource to the Pharmaceutical Professional.
This document provides information on WHO GMP compliance for Boswellia Serrata extract product Wokvel. It discusses the active ingredients in Boswellia Serrata, the composition and dosage of Wokvel tablets, indications for use, and required documentation for WHO GMP certification including site master file, water and air quality manuals, validation protocols, and quality management systems. It also summarizes the roles of regulatory bodies like CDSCO and DCGI in India and minimum documentation checklists for herbal drug products.
This document discusses Good Manufacturing Practices (GMP) for pharmaceuticals. It introduces GMP, explaining that GMP ensures pharmaceutical products are consistently manufactured and controlled to quality standards for their intended use. It also discusses the relationships between quality assurance (QA), GMP, and quality control (QC), explaining that QA oversees the whole system, GMP is the quality system for manufacturing, and QC tests samples of products. Current good manufacturing practices (cGMP) are also introduced as the GMP regulations enforced by the FDA to control manufacturing operations and assure drug identity, strength, quality and purity.
central and state Regulatory bodies in Indiasonaliph
The document discusses the central and state drug regulatory bodies in India. It outlines that the key regulatory bodies are the Ministry of Health and Family Welfare, Central Drug Standard Control Organization, Indian Pharmacopoeial Commission, Drug Controller General of India, and National Pharmaceutical Pricing Authority. These bodies regulate drug manufacturing, import, distribution, pricing and ensure drug quality, safety and efficacy. The document also provides details on roles of state drug regulatory authorities like the Food and Drug Administration of Maharashtra.
Overview Drug, Alternative Medicines, Medical Devices Registration in PakistanMuhammad Ali Jehangir
Overview of DRAP requirement regarding Drug Manufacturing And License Fee,Drug Registration and Drug Registration Fee , Drug Pricing, Enlistment and Enlistment Fee, Medical Devices and Medical Devices Fee
The document discusses administrative challenges facing India's drug regulatory authorities. It notes a lack of uniformity between the national regulator, CDSCO, and state regulators (SDRAs) due to their divided responsibilities, differing legal interpretations of drug laws, and limited coordination. This risks fragmentation in regulation. The document examines this issue and others like resources, transparency, and public outreach to develop policy recommendations for strengthening oversight.
This presentation consists of information related to Schedule M, a topic under #Drug_and_Cosmetics_Act. This presentation could be beneficial for the sake of the seminar in #Pharmaceutical_Jurisprudence for pharmacy students.
This document summarizes the key impacts of China's new Food Safety Law on infant formula, health foods, and special dietary foods. It discusses increased regulations for infant formula, including whole process quality control, product registration, and restrictions on sub-packaging and using the same formula for different brands. It also outlines the import process for infant formula and challenges import companies may face, such as ensuring formulas are registered and formulations comply with local policies.
IIMPORT AND REGISTRATION AS PER DRUG AND COSMETIC ACT Sagar Savale
The drug and cosmetic act was passed on 10th April, 1940.
Objective : To regulate the import, manufacture, distribution, and sale of Drug and Cosmetics.
All classes of the drugs and cosmetics imported into India, shall comply with the prescribed standards and labels.
Manufacture of all classes of drug require prior license.
This document outlines the voluntary certification process for food establishments in India. It describes the 3 categories of food establishments, the application and evaluation process, requirements for initial certification and continued surveillance, as well as procedures for granting, maintaining, and suspending certification. The objective is to promote food safety and hygiene through independent assessment and rating of food establishments.
The document discusses India's drug regulatory system. The Drug Controller General of India regulates drugs and medical devices in the country to ensure quality, safety and efficacy. New drugs require approval through a New Drug Application process which involves submitting documentation on manufacturing, non-clinical studies, and clinical trials for review. It takes about a year to review an NDA and various forms and fees are involved in the approval and import license application processes.
This ppt gives a holistic view and analysis of NPDS Act in India . This was made as a personal assignment during MPH , and have taken information from many resources available in the public domain .The idea of putting it here is to help and guide many who want to seek an information and increase their knowledge about the topic. I have taken full cognizance an given due recognition to the original authors and researchers in the REFERENCE slides .
The document discusses drug regulatory affairs and its importance in the pharmaceutical industry. It provides an overview of key concepts including:
- The roles and responsibilities of drug regulatory authorities globally and in Pakistan specifically, including the Drug Regulatory Authority of Pakistan (DRAP).
- The various laws and regulations governing drug development and approval in Pakistan, including the Drugs Act of 1976.
- The regulatory procedures involved in drug licensing and marketing authorization in Pakistan.
- The importance of regulatory compliance and understanding regulations for pharmaceutical professionals and companies to successfully develop and commercialize new drugs.
This document outlines administrative order no. 2014-0034 from the Philippines Department of Health Food and Drug Administration. It establishes rules for licensing drug establishments to ensure compliance with Good Manufacturing Practice, Good Distribution Practice, and other standards. It prescribes the use of electronic submissions and signatures. The order classifies different types of drug establishments and outlines requirements for licensing, variations, renewals, and inspections. It aims to align drug establishment operations with laws and international regulatory standards to ensure safety, efficacy and quality of drugs.
Dr.Lavanya- Laws pertaining to Ayurvedic drugsDr.Lavanya .S.A
This document summarizes various laws governing Ayurvedic drugs in India, including the Drug & Cosmetic Act of 1940, Drug & Magic Remedies Act of 1954, Prevention of Food Adulteration Act, Food Standards and Safety Act of 2006, and Narcotic Drugs and Psychotropic Substances Act of 1985. It provides details on key parts of acts like the Drug & Cosmetic Rules of 1945 and amendments made for regulation of Ayurvedic drugs. The document also lists some scheduled poisons and permitted excipients in Ayurvedic medicines.
This presentation contains legal requirements for labeling for pharmaceuticals, types of label, objective of label and recent advancement in labeling of pharmaceuticals.
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
This document outlines the regulatory requirements and approval procedures for drugs, cosmetics, medical devices, biological products, herbal medicines, and foods/nutraceuticals in India. It discusses the key regulatory bodies like the Central Drugs Standard Control Organization (CDSCO) and the application processes. For drugs, the new drug approval procedure is described involving applying to the DCGI and undergoing clinical trials and reviews. For other products, the document explains the application forms and documents required for approval from bodies like FSSAI.
The passage summarizes the major changes to food and drug regulation in the Philippines from the passage of the Food and Drug Administration Act of 2009. Key points:
- The new law created the Food and Drug Administration (FDA) under the Department of Health, headed by a Director-General, to oversee food, drug, medical device, and cosmetic regulation.
- It consolidated regulatory powers over these products under the FDA, affecting two existing agencies. The new law aims to protect public health and establish an effective regulatory system.
- Major changes include new powers for the FDA, reorganization within the Department of Health, and establishment of new units within the FDA. The FDA has since drafted new rules and
A drug inspector is responsible for monitoring and ensuring the safety, quality, and effectiveness of drugs from production to sale. To become a drug inspector, candidates must have a pharmacy or pharmaceutical science degree, 18 months of relevant work experience, and pass a written exam consisting of two papers testing knowledge of pharmacy and general knowledge. Drug inspectors have the power to inspect any premises or records involved in drug manufacturing, sample and test drugs, inspect licenses, and cancel licenses of businesses found to have quality or standards issues. The role requires skills in discipline, patience, self-confidence, and keeping updated in the pharmaceutical field.
(15 mph104) cdsco & fda guidelinesDishant shah
This document provides an overview of CDSCO and FDA guidelines for drug approval. It begins with an introduction to CDSCO as India's national regulatory body equivalent to agencies like the EMA and FDA. It describes CDSCO's organization, functions in approving drugs and devices, and guidelines. It then explains the Common Technical Document format used for drug submissions and its modules. Guidelines for areas like cosmetics, clinical trials, and bioavailability and bioequivalence are summarized. The document concludes with references to CDSCO and FDA websites for further information.
The document summarizes the key proposed amendments to the Drugs and Cosmetics Act from the 2013 bill. It outlines the establishment of a new Central Drugs Authority to regulate the import, manufacture, and sale of drugs, cosmetics and medical devices. It also creates new chapters on clinical trials, requiring permission and registration for any trials. Penalties are established for violations like conducting unauthorized trials or failing to provide proper compensation. The bill aims to modernize drug regulation in India through the new oversight body and additional rules for clinical research.
The European Commission Health and Consumers Directorate – General has published a draft “GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICES FOR ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE”.
The guideline addresses Quality systems, Personnel, Documentation, Order, Procedures, Records, Premises and Equipment, Receipts, Storage , Deliveries to Customers, Transfer of Information and Returns.
Following presentation is prepared by “ Drug Regulations” a non profit organization which provides free online resource to the Pharmaceutical Professional.
This document provides information on WHO GMP compliance for Boswellia Serrata extract product Wokvel. It discusses the active ingredients in Boswellia Serrata, the composition and dosage of Wokvel tablets, indications for use, and required documentation for WHO GMP certification including site master file, water and air quality manuals, validation protocols, and quality management systems. It also summarizes the roles of regulatory bodies like CDSCO and DCGI in India and minimum documentation checklists for herbal drug products.
This document discusses Good Manufacturing Practices (GMP) for pharmaceuticals. It introduces GMP, explaining that GMP ensures pharmaceutical products are consistently manufactured and controlled to quality standards for their intended use. It also discusses the relationships between quality assurance (QA), GMP, and quality control (QC), explaining that QA oversees the whole system, GMP is the quality system for manufacturing, and QC tests samples of products. Current good manufacturing practices (cGMP) are also introduced as the GMP regulations enforced by the FDA to control manufacturing operations and assure drug identity, strength, quality and purity.
central and state Regulatory bodies in Indiasonaliph
The document discusses the central and state drug regulatory bodies in India. It outlines that the key regulatory bodies are the Ministry of Health and Family Welfare, Central Drug Standard Control Organization, Indian Pharmacopoeial Commission, Drug Controller General of India, and National Pharmaceutical Pricing Authority. These bodies regulate drug manufacturing, import, distribution, pricing and ensure drug quality, safety and efficacy. The document also provides details on roles of state drug regulatory authorities like the Food and Drug Administration of Maharashtra.
Overview Drug, Alternative Medicines, Medical Devices Registration in PakistanMuhammad Ali Jehangir
Overview of DRAP requirement regarding Drug Manufacturing And License Fee,Drug Registration and Drug Registration Fee , Drug Pricing, Enlistment and Enlistment Fee, Medical Devices and Medical Devices Fee
The document discusses administrative challenges facing India's drug regulatory authorities. It notes a lack of uniformity between the national regulator, CDSCO, and state regulators (SDRAs) due to their divided responsibilities, differing legal interpretations of drug laws, and limited coordination. This risks fragmentation in regulation. The document examines this issue and others like resources, transparency, and public outreach to develop policy recommendations for strengthening oversight.
This presentation consists of information related to Schedule M, a topic under #Drug_and_Cosmetics_Act. This presentation could be beneficial for the sake of the seminar in #Pharmaceutical_Jurisprudence for pharmacy students.
This document summarizes the key impacts of China's new Food Safety Law on infant formula, health foods, and special dietary foods. It discusses increased regulations for infant formula, including whole process quality control, product registration, and restrictions on sub-packaging and using the same formula for different brands. It also outlines the import process for infant formula and challenges import companies may face, such as ensuring formulas are registered and formulations comply with local policies.
IIMPORT AND REGISTRATION AS PER DRUG AND COSMETIC ACT Sagar Savale
The drug and cosmetic act was passed on 10th April, 1940.
Objective : To regulate the import, manufacture, distribution, and sale of Drug and Cosmetics.
All classes of the drugs and cosmetics imported into India, shall comply with the prescribed standards and labels.
Manufacture of all classes of drug require prior license.
This document outlines the voluntary certification process for food establishments in India. It describes the 3 categories of food establishments, the application and evaluation process, requirements for initial certification and continued surveillance, as well as procedures for granting, maintaining, and suspending certification. The objective is to promote food safety and hygiene through independent assessment and rating of food establishments.
The document discusses India's drug regulatory system. The Drug Controller General of India regulates drugs and medical devices in the country to ensure quality, safety and efficacy. New drugs require approval through a New Drug Application process which involves submitting documentation on manufacturing, non-clinical studies, and clinical trials for review. It takes about a year to review an NDA and various forms and fees are involved in the approval and import license application processes.
This ppt gives a holistic view and analysis of NPDS Act in India . This was made as a personal assignment during MPH , and have taken information from many resources available in the public domain .The idea of putting it here is to help and guide many who want to seek an information and increase their knowledge about the topic. I have taken full cognizance an given due recognition to the original authors and researchers in the REFERENCE slides .
The document discusses drug regulatory affairs and its importance in the pharmaceutical industry. It provides an overview of key concepts including:
- The roles and responsibilities of drug regulatory authorities globally and in Pakistan specifically, including the Drug Regulatory Authority of Pakistan (DRAP).
- The various laws and regulations governing drug development and approval in Pakistan, including the Drugs Act of 1976.
- The regulatory procedures involved in drug licensing and marketing authorization in Pakistan.
- The importance of regulatory compliance and understanding regulations for pharmaceutical professionals and companies to successfully develop and commercialize new drugs.
This document discusses import and export regulations for drugs in India. It provides details on key facts about the Indian pharmaceutical industry, including that India is the largest provider of generic drugs globally. It also outlines the agencies that regulate drug import and export, such as the Central Drugs Standard Control Organisation. The document discusses export and import licensing procedures, quality control and inspection requirements, labeling and packaging standards, and conditions for granting import licenses.
National Pharmaceutical Pricing Authority-WPS Office.pptxSudipta Roy
This document discusses the objectives and approaches of the National Pharmaceutical Pricing Authority in India. The key objectives are to ensure availability of affordable essential drugs, strengthen domestic production capacity and quality, encourage research and development focused on diseases in India, and create incentives for investment in the pharmaceutical industry. The approaches include establishing committees to support R&D, gradually reducing the scope of price controls, allowing more foreign investment and imports, exempting new drugs from price controls, and monitoring prices.
In 2017, Colombia put in force a regulatory framework on safe and informed access to medical and scientific use of cannabis and its derivatives. The regulation regulates the cultivation, sale, derivatives, and use of cannabis seeds for medicinal and scientific purposes.
Doing business with medical cannabis
What regulations does Colombia have for growing and processing medical cannabis? What business opportunities are there in this field?
Legislation in respect of Homeopathic PharmacyRamJyothis
The document summarizes key legislation related to homeopathic pharmacy in India. It discusses the origin of pharmaceutical legislation beginning in 1927 and the recommendations of committees that helped form acts like the Drugs and Cosmetics Act of 1940. The act established standards for importing, manufacturing, and selling drugs and set up licensing for pharmacists. It also covers laws specific to homeopathic medicines regarding licensing of sellers and manufacturers, conditions of licenses, labeling, and restrictions on packaging and alcohol content. The document traces the evolution of drug policy and regulation in India.
Drug Regulations in India Dr Surinder Singh.pdfwasimankhan
This document discusses India's pharmaceutical industry and regulatory system. It provides details on:
- The size and growth of India's domestic and export pharmaceutical market
- India's role as a major supplier of drugs to African countries
- The laws and regulatory agencies that govern drug production, import, and sale in India
- Initiatives taken by the Indian government to address issues like counterfeit drugs and ensure drug quality standards.
The document provides an overview of India's drug regulatory system, including:
- The Central Drugs Standard Control Organization (CDSCO) regulates drug approval, clinical trials, GMP, and other functions. It is headed by the Drug Controller General of India.
- The drug approval process involves submitting an application, treasury challan, and details on bulk drug sources. The Drugs and Cosmetics Act of 1940 and Rules of 1945 provide the legal framework and establish licensing requirements.
- There are various types of manufacturing, sale, import, and testing licenses issued under the Act based on the schedule and category of drugs. The organizational structure, approval process, legal framework and license types are described.
This document provides an overview of Colombia's growing cannabis industry, including regulatory developments, license types, definitions, and frequently asked questions. The main points covered are:
- Colombia has established one of the most complete regulatory frameworks in the region for the cannabis industry, covering the entire value chain from cultivation to production to exports.
- There are various license types available for different activities like cultivation, manufacturing, research, and exports. Requirements vary by license type.
- Common questions addressed include import/export procedures, manufacturing finished products, and operations within free trade zones.
- The information is intended to help domestic and foreign investors understand opportunities in Colombia's cannabis sector.
The document discusses the administration of the Drugs and Cosmetics Act and Rules in India. It outlines the roles and qualifications of government analysts, drugs inspectors, and their powers and duties. Government analysts are appointed by state and central governments to analyze drug and cosmetic samples. They must have qualifications in medicine, science, pharmacy or pharmaceutical chemistry. Drugs inspectors inspect premises where drugs are manufactured and sold. They collect samples, examine records, and seize stocks if needed. Inspectors investigate complaints and work to detect illegal drug sales.
The document discusses the administration of the Drugs and Cosmetics Act and Rules in India. It outlines the roles and qualifications of government analysts, drugs inspectors, and their powers and duties. Government analysts are appointed by state and central governments to analyze drug and cosmetic samples. They must have qualifications in medicine, science, pharmacy or pharmaceutical chemistry. Drugs inspectors inspect premises where drugs are manufactured and sold. They collect samples which are sent to government analysts. Based on the analysis, drugs may be destroyed if substandard or auctioned if of standard quality.
This document summarizes the administration and enforcement of the Drugs and Cosmetics Act and Rules in India. It discusses the roles of various analytical, executive, and advisory bodies involved in drug regulation. It also describes the qualifications, duties, and powers of key enforcement positions like Government Analysts and Drugs Inspectors. Government Analysts test and analyze drug samples collected by inspectors and provide reports. Drugs Inspectors are appointed to inspect drug manufacturing and sales premises, collect samples, and investigate complaints. They have powers to enter and search premises, stop and search vehicles, and examine records if an offense is suspected.
Drug trafficking and the role of ndps act in curbing the menace of organized ...gagan deep
The document discusses India's Narcotic Drugs and Psychotropic Substances (NDPS) Act of 1985, which was enacted to strengthen drug laws and curb organized crime related to drug trafficking. It defines key terms, outlines the objectives of the act to provide stricter regulation of drugs and psychotropic substances, and establishes authorities like the Narcotics Control Bureau to enforce the law. The NDPS Act prohibits certain drug-related activities and empowers the central government to control and regulate authorized operations. It also prescribes sanctions for non-compliance with the law's provisions related to substances like opium, cannabis, cocaine, and psychotropic drugs.
This document provides an overview of the global and Indian pharmaceutical industries. It discusses the evolution and growth of the industries from the 1940s to present day. Key points include increased regulation and costs driving consolidation, pressure to develop new drugs, and the industries transforming from US/EU focused to global. The Indian industry is self-reliant in drug production and a low-cost source for generics facing patent expiration globally. The document also outlines regulations and classifications within the industries.
This document provides an overview of the generic drug registration processes in Egypt and Saudi Arabia. In Egypt, registration follows a "box system" where similar drugs are grouped in boxes. The multi-step process involves several committees and can take over a year. Saudi Arabia uses an online eCTD submission process that is assessed in 120 days. Both countries require bioequivalence and stability studies as well as adherence to their specific CTD guidelines. Overall, the document compares the regulatory bodies, legislation, registration procedures and requirements for generic drug approval between the two countries.
The drug regulatory authority develops and implements legislation and regulations regarding pharmaceuticals to ensure drug quality, safety and efficacy. It establishes rules for drug manufacture, distribution, clinical trials and more. The key agencies are the Ministry of Health and Family Welfare, Central Drugs Standard Control Organization, Indian Pharmacopoeia Commission and National Pharmaceutical Pricing Authority. The CDSCO regulates drugs and medical devices in India under the Ministry of Health. State drug control organizations like the FDA Maharashtra enforce drug laws at the local level.
Similar to Presentation: Regulatory issues relating to the growing and cultivation of cannabis for medicinal purposes (20)
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...TGA Australia
The document discusses several regulatory reforms for listed medicines in Australia, including:
1. Permitted indications which provide a list of approved health benefit claims for listed medicines and require sponsors to select from this list, improving transparency.
2. An assessed listed pathway which allows pre-market evaluation of efficacy claims, providing access to higher-level health claims.
3. A "TGA assessed" label claim indicating the medicine's efficacy has been evaluated, improving consumer awareness and confidence.
4. Two years of market exclusivity for sponsors who apply for and are approved for new permitted ingredients.
Regulation, ethics and reimbursement of novel biological therapies in Austral...TGA Australia
The document provides an overview of novel biological therapies such as gene therapy, cell therapy, and tissue engineering in Australia. It discusses the regulatory pathways through the Therapeutic Goods Administration (TGA) for approval of these therapies. Clinical trials of novel biological therapies must be submitted through the CTX scheme for approval rather than just notification. Guidelines from the European Medicines Agency are a good resource for requirements for registration and approval of these therapies in Australia. Risks associated with gene therapy include potential for delayed adverse effects, off-target effects, insertional mutagenesis, and immune responses.
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
The document summarizes proposed regulatory reforms from the Therapeutic Goods Administration (TGA) Medical Devices Branch. It discusses proposed changes to the regulation of software as medical devices, personalized medical devices including 3D printed devices, essential principles, conformity assessment procedures, requirements for devices used in clinical trials, and clarifying requirements for systems and procedure packs. The proposed reforms aim to modernize regulations, increase alignment with international standards, and ensure oversight is risk-based and promotes safety. Public consultations will be held on the proposed changes.
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...TGA Australia
The document provides an overview of Australia's Good Manufacturing Practice (GMP) Clearance Framework. It discusses the legislative basis for manufacturing requirements, the roles and activities of the Manufacturing Quality Branch, and the two pathways for obtaining a GMP Clearance - a desk-based assessment through a Mutual Recognition Agreement or Compliance Verification, or an on-site TGA inspection. It also outlines the history of GMP Clearance, recognized authorities through agreements like MRAs, and the MRA assessment pathway.
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
Presentation: The challenges of regulating direct to consumer digital medical...TGA Australia
The document discusses the challenges of regulating direct-to-consumer digital medical devices. It describes what digital medical devices are, including connected devices, telehealth, apps, and wearables. The Therapeutic Goods Administration (TGA) regulates medical devices in Australia to ensure they are safe and effective. However, digital devices pose new challenges as many are software-based and consumers may not understand their intended medical purpose. The TGA must determine how to appropriately apply existing regulations to these new technologies.
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
The document provides background information on Australia's Therapeutic Goods Advertising legislation and Code. It discusses key aspects of the legislation including:
- The Therapeutic Goods Act and Regulations set advertising requirements for therapeutic goods. Advertising must also comply with the Australian Consumer Law.
- The Act prohibits off-label promotion and requires pre-approval of medicine ads in certain media. It also places restrictions on advertising certain medical conditions.
- The Therapeutic Goods Advertising Code provides the framework for ensuring advertising is conducted properly and does not mislead consumers. It was recently revised to provide more clarity.
- The Code applies broadly to any advertising of therapeutic goods. It exempts genuine news reporting and ads directed to health
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Presentation: Regulatory issues relating to the growing and cultivation of cannabis for medicinal purposes
1. Regulatory issues relating to the growing and
cultivation of cannabis for medicinal purposes
RACI Pharmaceutical Science Group (NSW)
Bill Turner, Head of the Office of Drug Control
28 March 2017
2. What is the Office of Drug Control?
• Part of the Health Products Regulation Group,
Department of Health
• Administers:
• Regulations 5, 5H and 5G of the Customs (Prohibited
Imports) Regulations 1956
• Regulations 10 and 10A of the Customs (Prohibited
Exports Regulations 1958
• The Narcotic Drugs Act 1967
4. Cultivation and
Production
Production is the
removal of the cannabis
from the cannabis plant
Medicinal cannabis
licence – can authorise
cultivation or
production or both
Cannabis research
licence – authorises
research into the
medicinal properties of
cannabis
5. Cannabis licence requirements
• Fit and Proper Persons test set out in legislation
• Must be of good character
• Must be financial
• Must have the capacity and capability to undertake a
cannabis cultivation business
• Must not have engaged in ‘conduct constituting a serious
offence’ in the past 10 years
• Must make appropriate security arrangements
• For a medicinal cannabis licence, must have a business
relationship with a licensed manufacturer
• For a cannabis research licence, must be undertaking
appropriate research
7. Manufacture licence requirements
• Fit and Proper Persons test set out in legislation
• Must be of good character
• Must be financial
• Must have the capacity and capability to undertake a
cannabis manufacture business
• Must not have engaged in ‘conduct constituting a serious
offence’ in the past 10 years
• Must make appropriate security arrangements
• Must be able to demonstrate that supply will be in
accordance with the Therapeutic Goods Act 1989
8. Import
Import Licence –
Regulation 5 of the
Customs (PI) Regulations
Import permission for
each consignment –
Regulation 5 of the
Customs (PI) Regulations
9. Import requirements
• Fit and Proper Persons test
• Licensing process is to determine if the applicant is a
suitable person to be importing and handling narcotic
substances
• Permitting process is the ‘international currency’ system –
an import permission indicates a country’s willingness to
import; this allows the exporting country to issue ‘export
permission’.
• In the international trading system, the import permission
and the export permission ‘marry up’ to track quantities
traded and prevent over-production
• Subject to record keeping requirements to ensure
appropriate use